NCT07675668 QG101-23-0 Hypertrophic Cardiomyopathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07675668—Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07675668 is a hot trial to watch

Hypertrophic Cardiomyopathy is no longer one homogeneous development market. The most consequential programs increasingly compete through a specific mechanism, biomarker, treatment line, delivery strategy or endpoint architecture. NCT07675668 is notable because it tests QG101-23-0 in a Phase 2 design with To evaluate the safety and tolerability of Aom0304 in participants with HCM as a primary decision variable. The wider PatSnap topic query returned 254 trial records and 91 result records, so differentiation depends on evidence quality rather than activity alone.

PatSnap Clinical Trials MCP makes the protocol fields machine-readable, while the companion asset and organization servers add mechanism and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The design should be read as an evidence architecture, not just a phase label. The primary endpoint—To evaluate the safety and tolerability of Aom0304 in participants with HCM—determines what uncertainty this study can resolve. The reported time frame is Baseline to week 12. Enrollment of 56 participants and geography in Not reported shape statistical precision, operational risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.

Benchmark readouts in the same clinical field

• A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy (Phase 3): Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)(Mean) = -1.24 mL/kg/min (Standard Deviation, 2.186); Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)(Mean) = 1.07 mL/kg/min (Standard Deviation, 2.767); Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)(Mean): Least Squares Mean Difference = 2.30(95% CI, 1.52 - 3.07), P-Value = <0.0001; Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)(Mean): Least Squares Mean Difference = 2.30(95% CI, 1.52 - 3.07), P-Value = <0.0001; Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)(Mean): Least Squares Mean Difference = 2.30(95% CI, 1.52 - 3.07), P-Value = <0.0001.
• A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction (MERCUTIO) (Phase 2): Participants with at least one adverse events in Part A = 15 Participants ; -; -; -; -.
• Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Patient-Reported Health Status Analysis up to 78 Weeks in the EXPLORER-CN Study (Phase 2): KCCQ-23 CSS = 7.1 point ; KCCQ-23 CSS = 5.7 point ; KCCQ-23 CSS = 7.3 point .

These result records are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, line of therapy, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.

Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: QG101-23-0 (Phase 2; target not reported).

Company & Deal Intelligence context: Amckaus PTY LTD..

The sponsor profile matters because a trial's strategic value depends on more than scientific rationale. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.

White space around this program

1. Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
2. Clinically interpretable endpoints: outcomes that connect biological activity with function, symptoms, survival or treatment burden.
3. Sequencing evidence: randomized data after the most relevant contemporary standard of care.
4. Broader external validity: evidence across additional geographies, demographic groups and real-world care settings.
5. Operational differentiation: a development path that closes the readout gap without sacrificing safety monitoring or durability.

What to monitor next

Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.

Bottom line

NCT07675668 is a focused lens on Hypertrophic Cardiomyopathy development. Its value will be determined by whether QG101-23-0 can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from topic-level benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.